Axogen, Inc.

AXGN

Axogen, Inc.

AXGN

Insider Sentiment (TTM):

Last Purchase:2024-08-08Last Sale:2026-05-08Shares Purchased (TTM):0Shares Sold (TTM):412,643

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:48,723,601Shares Outstanding:51,591,504Institutional Ownership Pct.:94.44%

Earnings Market Reaction:

Filing Date:2026-04-28Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Electromedical & Electrotherapeutic Apparatus

MDT MASI LIVN TMDX ITGR CNMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	83	36	24	20	18	28	19	19	16	31	31	23
Restricted Cash	2	4	4	6	6	6	6	6	6	6	6	6
Short Term Investments	19	6	12	10	4	6	6	2	2	0	1	11
Accounts Receivable Net Current	28	26	31	28	26	24	25	25	24	25	23	22
Inventory Net	46	42	41	37	36	33	29	28	28	23	23	21
Prepaid Expense And Other Assets Current	7	6	3	3	3	2	2	2	3	3	3	3
Assets Current	185	120	114	103	93	99	86	82	79	88	87	86
Property Plant And Equipment And Finance Lease Rig…	83	82	82	82	83	85	86	87	88	89	89	87
Operating Lease Right Of Use Asset	14	13	13	14	14	14	15	15	15	16	14	14
Intangible Assets Net Excluding Goodwill	7	7	6	6	6	6	5	5	5	5	4	4
Other Assets Noncurrent	0	-	-	-	-	-	-	-	-	-	-	-
Assets	289	222	216	205	196	204	192	189	187	197	195	192
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	24	21	26	23	20	29	21	22	21	29	26	23
Liabilities Current	26	24	28	25	22	31	23	23	23	30	27	24
Long Term Debt Noncurrent	0	48	48	48	48	47	47	47	47	47	46	46
Derivative Liabilities Noncurrent	0	4	2	2	3	2	2	2	3	3	4	4
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	-	0	-	-
Liabilities	45	93	96	93	91	100	93	93	93	101	97	94
Stockholders Equity
Common Stock Value	1	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	571	435	414	406	400	395	391	385	381	377	375	370
Retained Earnings Accumulated Deficit	-327	-307	-294	-295	-295	-291	-292	-290	-288	-281	-277	-273
Stockholders Equity	245	129	121	112	105	104	99	96	93	96	98	97
Liabilities And Stockholders Equity	289	222	216	205	196	204	192	189	187	197	195	192
Allowance For Doubtful Accounts Receivable Current	1	1	1	1	1	1	1	1	1	0	0	1
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	53	47	46	46	46	44	44	44	44	43	43	43
Shares Outstanding	53	47	46	46	46	44	44	44	44	43	43	43

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.60%	6.79%	-5.10%	-	-	-	-	-	-	-	-	-
2025	-13.50%	-16.60%	6.20%	17.64%	25.07%	32.43%	20.76%	43.73%	39.42%	-5.29%	18.46%	26.12%
2024	6.63%	19.05%	55.10%	22.90%	28.88%	24.39%	4.75%	25.55%	36.70%	-8.94%	-19.99%	-39.21%
2023	-5.15%	-2.04%	-8.69%	-5.55%	-25.04%	-44.08%	27.88%	26.95%	77.14%	-10.23%	-26.25%	-30.26%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	7.10	5.11	4.09	4.14	4.28	3.24	3.74	3.51	3.43	2.89	3.28	3.60
Quick Ratio	5.07	3.04	2.52	2.56	2.50	2.08	2.39	2.23	2.09	2.04	2.32	2.61
Working Capital	158.70M	96.87M	86.45M	78.44M	71.33M	68.61M	63.22M	58.85M	55.73M	57.57M	60.79M	62.24M
Leverage & Debt
Debt to Equity	0.18	0.72	0.79	0.83	0.86	0.96	0.93	0.97	1.00	1.06	0.99	0.97
Interest Coverage TTM	-1.47	-1.02	0.51	0.22	-0.05	-0.40	-1.03	-1.70	-3.63	-7.57	-23.16	-93.23
Debt Ratio	0.15	0.42	0.44	0.45	0.46	0.49	0.48	0.49	0.50	0.51	0.50	0.49
Efficiency & Turnover
Asset Turnover TTM	0.98	1.06	1.05	1.03	1.02	0.94	0.94	0.91	0.87	0.81	0.78	0.76
Days Sales Outstanding TTM	41.86	40.74	47.09	47.75	47.39	47.98	48.33	49.15	51.82	54.32	53.49	51.74
Receivables Turnover TTM	8.72	8.96	7.75	7.64	7.70	7.61	7.55	7.43	7.04	6.72	6.82	7.05
Per Share Metrics
Diluted EPS TTM	-0.61	-0.34	-0.04	-0.10	-0.16	-0.23	-0.33	-0.38	-0.49	-0.51	-0.54	-0.55
Free Cash Flow Per Share TTM	0.18	-0.06	0.07	0.11	0.03	0.03	-0.19	-0.31	-0.49	-0.46	-0.54	-0.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	75.01%	74.31%	74.76%	74.27%	74.18%	75.79%	75.43%	75.91%	76.96%	76.64%	78.73%	80.40%
Operating Profit Margin TTM	-3.79%	-3.49%	1.84%	0.84%	-0.20%	-1.75%	-4.70%	-7.04%	-11.41%	-13.50%	-15.68%	-16.70%
Net Profit Margin TTM	-13.21%	-6.97%	-0.98%	-2.29%	-3.68%	-5.32%	-7.91%	-9.53%	-13.00%	-13.66%	-15.26%	-15.86%
Growth Metrics
Net Revenue Growth (1Y)	22.41%	20.21%	18.72%	17.17%	18.81%	17.81%	18.79%	17.26%	13.51%	14.74%	13.66%	15.40%
Net Income Growth (1Y)	339.10%	57.60%	-85.34%	-71.80%	-66.33%	-54.12%	-38.43%	-29.53%	-13.32%	-24.98%	-19.37%	-25.84%
EPS Growth (1Y)	284.74%	51.46%	-86.17%	-73.24%	-67.80%	-55.55%	-39.64%	-30.90%	-14.65%	-26.37%	-20.87%	-27.34%
Valuation Metrics
P/E TTM	-54.34	-95.98	-395.55	-107.18	-116.75	-73.20	-43.00	-19.14	-16.40	-13.49	-9.26	-16.68
P/B TTM	6.98	11.70	6.87	4.45	7.94	7.02	6.19	3.31	3.75	3.06	2.20	4.03
P/S TTM	7.18	6.69	3.86	2.46	4.30	3.89	3.40	1.82	2.13	1.84	1.41	2.65
Market Cap	1.71B	1.51B	829.46M	499.78M	836.28M	729.37M	615.23M	316.48M	348.89M	292.86M	215.11M	391.33M
Enterprise Value	1.62B	1.52B	849.72M	521.69M	859.90M	743.31M	637.84M	338.34M	374.00M	302.44M	224.39M	408.02M
Calculated Values
Free Cash Flow TTM	9.28M	-2.93M	3.34M	4.94M	1.19M	1.43M	-8.31M	-13.67M	-21.05M	-19.59M	-23.17M	-26.17M
Net Debt	-84.65M	8.84M	20.26M	21.90M	23.62M	13.94M	22.61M	21.86M	25.11M	9.58M	9.28M	16.68M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-08Sale

Owner: Wendell, Amy Mcbride

Title: -

Shares: 1,647

Price/Share: $42.60

Value: $70,162.20

Shares Owned: 93,826

Relationship: Director

Ownership: Direct

2026-05-07Sale

Owner: Quackenbush, Doris

Title: Sales VP

Shares: 3,878

Price/Share: $43.51

Value: $168,731.78

Shares Owned: 92,416

Relationship: Officer

Ownership: Direct

2026-05-07Sale

Owner: Johnson, John

Title: -

Shares: 11,050

Price/Share: $43.26

Value: $478,023.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-05-07Sale

Owner: Kemp, Jens

Title: Chief Marketing Officer

Shares: 4,000

Price/Share: $43.44

Value: $173,760.00

Shares Owned: 72,451

Relationship: Officer

Ownership: Direct

2026-05-07Sale

Owner: Weiler, Kathy Johnson

Title: -

Shares: 16,344

Price/Share: $44.09

Value: $720,606.96

Shares Owned: -

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-08	Wendell, Amy Mcbride	Director	-	Direct	Sale	1,647	42.60	$70,162.20	93,826	4
2026-05-07	Quackenbush, Doris	Officer	Sales VP	Direct	Sale	3,878	43.51	$168,731.78	92,416	4
2026-05-07	Johnson, John	Director	-	Direct	Sale	11,050	43.26	$478,023.00	0	4
2026-05-07	Kemp, Jens	Officer	Chief Marketing Officer	Direct	Sale	4,000	43.44	$173,760.00	72,451	4
2026-05-07	Weiler, Kathy Johnson	Director	-	Direct	Sale	16,344	44.09	$720,606.96	0	4
2026-05-07	Hartley, Lindsey Marie	Officer	CFO	Direct	Sale	1,051	43.67	$45,897.17	62,756	4
2026-03-16	Devinney, Erick Wayne	Officer	Chief Innovation Officer	Direct	Sale	5,221	32.84	$171,457.64	262,781	4
2025-12-16	Wendell, Amy Mcbride	Director	-	Direct	Sale	43,684	29.31	$1,280,378.04	93,826	4
2025-12-16	Weiler, Kathy Johnson	Director	-	Direct	Sale	46,653	29.55	$1,378,596.15	0	4
2025-12-15	Hartley, Lindsey Marie	Officer	CFO	Direct	Sale	14,812	29.86	$442,286.32	31,376	4
2025-12-11	Began, Marc A	Officer	EVP & General Counsel	Direct	Sale	13,222	30.00	$396,660.00	18,285	4
2025-12-10	Dale, Michael D	Officer	Chief Executive Officer	Direct	Sale	25,000	30.00	$750,000.00	63,537	4
2025-12-09	Kemp, Jens	Officer	Chief Marketing Officer	Direct	Sale	8,156	31.21	$254,548.76	46,030	4
2025-12-09	Began, Marc A	Officer	EVP & General Counsel	Direct	Sale	9,278	31.21	$289,566.38	31,507	4
2025-12-09	Tyndall, Joseph A.	Director	-	Direct	Sale	25,108	30.98	$777,845.84	0	4
2025-12-09	Johnson, John	Director	-	Direct	Sale	21,686	29.98	$650,146.28	0	4
2025-12-09	Thomas, Paul	Director	-	Direct	Sale	21,399	29.61	$633,624.39	13,528	4
2025-12-09	Devinney, Erick Wayne	Officer	Chief Innovation Officer	Direct	Sale	19,517	31.21	$609,125.57	241,132	4
2025-12-09	Dale, Michael D	Officer	Chief Executive Officer	Direct	Sale	61,463	31.21	$1,918,260.23	88,537	4
2025-12-08	Hartley, Lindsey Marie	Officer	CFO	Direct	Sale	14,387	31.56	$454,053.72	31,376	4
2025-11-11	Burke, William P. Mr.	Director	-	Direct	Sale	3,591	24.02	$86,255.82	100	4
2025-11-06	Burke, William P. Mr.	Director	-	Direct	Sale	5,347	24.01	$128,381.47	100	4
2025-10-30	Burke, William P. Mr.	Director	-	Direct	Sale	18,248	23.00	$419,704.00	100	4
2025-10-22	Burke, William P. Mr.	Director	-	Direct	Sale	1,457	18.02	$26,255.14	100	4
2025-10-06	Burke, William P. Mr.	Director	-	Direct	Sale	736	18.00	$13,248.00	1,557	4
2025-10-03	Burke, William P. Mr.	Director	-	Direct	Sale	14,571	18.21	$265,337.91	2,293	4
2025-09-16	Devinney, Erick Wayne	Officer	Chief Innovation Officer	Direct	Sale	1,137	16.29	$18,521.73	220,649	4
2025-06-10	Tyndall, Joseph A.	Director	-	Direct	Sale	26,931	10.72	$288,700.32	0	4
2025-06-09	Johnson, John	Director	-	Direct	Sale	4,073	10.61	$43,214.53	24,943	4
2025-06-09	Levine, Alan M	Director	-	Direct	Sale	4,073	10.61	$43,214.53	36,743	4
2025-06-09	Weiler, Kathy Johnson	Director	-	Direct	Sale	4,073	10.61	$43,214.53	6,580	4
2025-06-09	Wendell, Amy Mcbride	Director	-	Direct	Sale	4,073	10.61	$43,214.53	93,826	4
2025-06-09	Neels, Guido J	Director	-	Direct	Sale	4,073	10.61	$43,214.53	86,743	4
2025-06-09	Burke, William P. Mr.	Director	-	Direct	Sale	4,073	10.61	$43,214.53	24,484	4
2025-05-22	Tyndall, Joseph A.	Director	-	Direct	Sale	20,062	11.20	$224,694.40	15,345	4
2025-05-19	Tyndall, Joseph A.	Director	-	Direct	Sale	2,525	11.63	$29,365.75	22,557	4
2025-03-19	Devinney, Erick Wayne	Officer	Chief Innovation Officer	Direct	Sale	15,111	17.50	$264,442.50	217,762	4
2025-03-03	Wendell, Amy Mcbride	Director	-	Direct	Sale	5,000	20.02	$100,100.00	97,899	4
2024-08-08	Tyndall, Joseph A.	Director	-	Direct	Purchase	2,525	10.50	$26,512.50	25,082	5
2024-03-21	Devinney, Erick Wayne	Officer	Chief Innovation Officer	Direct	Sale	4,578	7.68	$35,159.04	165,661	4
2024-03-21	Zaderej, Karen L.	Director,Officer	CEO	Direct	Sale	39,280	7.68	$301,670.40	1,124,565	4
2024-03-21	Donovan, Michael Patrick	Officer	VP Operations	Direct	Sale	6,033	7.68	$46,333.44	37,992	4
2024-03-21	Scopelianos, Angelo	Officer	Chief R&D Officer	Direct	Sale	6,881	7.68	$52,846.08	52,999	4
2024-03-07	Donovan, Michael Patrick	Officer	VP Operations	Direct	Sale	36,310	8.81	$319,891.10	35,708	4
2024-03-07	Freitag, Gregory Gene	Director	-	Direct	Sale	25,000	9.00	$225,000.00	271,594	4
2023-12-11	Mariani, Peter J	Officer	EVP & Chief Financial Officer	Direct	Sale	12,500	7.51	$93,875.00	63,603	4
2023-09-06	Wendell, Amy Mcbride	Director	-	Direct	Purchase	10,000	6.22	$62,200.00	80,342	4
2023-08-23	Burke, William P. Mr.	Director	-	Indirect	Purchase	10,000	6.56	$65,600.00	10,000	4
2023-08-16	Neels, Guido J	Director	-	Direct	Purchase	10,000	6.11	$61,100.00	68,259	4
2023-06-01	Freitag, Gregory Gene	Director	-	Direct	Sale	41,980	8.70	$365,226.00	290,135	4
2023-05-23	Freitag, Gregory Gene	Director	-	Direct	Sale	7,468	9.22	$68,854.96	332,115	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

94.44%

Inst. Shares: 48,723,601

Shares Outstanding: 51,591,504

2025-12-31

90.59%

Inst. Shares: 41,718,439

Shares Outstanding: 46,050,266

2025-09-30

86.17%

Inst. Shares: 40,063,889

Shares Outstanding: 46,494,598

2025-06-30

84.46%

Inst. Shares: 38,904,982

Shares Outstanding: 46,063,092

2025-03-31

84.23%

Inst. Shares: 38,076,562

Shares Outstanding: 45,204,076

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	48,723,601	51,591,504	94.44%
2025-12-31	41,718,439	46,050,266	90.59%
2025-09-30	40,063,889	46,494,598	86.17%
2025-06-30	38,904,982	46,063,092	84.46%
2025-03-31	38,076,562	45,204,076	84.23%
2024-12-31	35,230,513	44,257,754	79.60%
2024-09-30	36,012,259	43,882,110	82.07%
2024-06-30	34,823,750	43,713,313	79.66%
2024-03-31	33,037,380	43,233,149	76.42%
2023-12-31	31,400,504	42,878,543	73.23%
2023-09-30	31,381,974	43,022,328	72.94%
2023-06-30	30,836,465	42,862,384	71.94%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Axogen, Inc. (AXGN) — SEC Financial Statements & Analysis

Axogen, Inc. (AXGN) is a electromedical & electrotherapeutic apparatus company, incorporated in MN. Axogen, Inc. trades on Nasdaq as: AXGN. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Axogen, Inc. reported a 22.41% year-over-year revenue growth, a Gross Profit Margin of 75.01% (TTM), a Debt-to-Equity ratio of 0.18x, a Price-to-Sales (P/S) ratio of 7.18x (TTM), a Price-to-Book (P/B) ratio of 6.98 (TTM), at a market cap of $1.71B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 22.41%
Gross Profit Margin TTM: 75.01%
Debt To Equity: 0.18x
P/S TTM: 7.18x
P/B TTM: 6.98
Market Cap: $1.71B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Axogen, Inc. in?

Axogen, Inc. (AXGN) operates in the Electromedical & Electrotherapeutic Apparatus industry.

What is AXGN's market cap?

Axogen, Inc. (AXGN) has a market capitalization of $1.71B as of 2026-03-31.

What exchange does AXGN trade on?

Axogen, Inc. (AXGN) trades on the Nasdaq.

Where is Axogen, Inc. incorporated?

Axogen, Inc. is incorporated in MN.

Axogen, Inc. (AXGN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.